One Capital Management LLC Makes New $1.57 Million Investment in GeneDx Holdings Corp. $WGS

One Capital Management LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 12,053 shares of the company’s stock, valued at approximately $1,568,000.

Other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp grew its holdings in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of GeneDx in the fourth quarter valued at approximately $35,000. Quarry LP grew its holdings in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in shares of GeneDx in the third quarter valued at approximately $65,000. Finally, AlphaQuest LLC grew its holdings in shares of GeneDx by 70.8% in the third quarter. AlphaQuest LLC now owns 1,303 shares of the company’s stock valued at $140,000 after acquiring an additional 540 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Trading Down 0.2%

NASDAQ:WGS opened at $53.02 on Thursday. The company has a market cap of $1.57 billion, a P/E ratio of -19.78 and a beta of 1.96. The stock’s fifty day moving average price is $55.99 and its two-hundred day moving average price is $93.70. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last posted its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the prior year, the company earned ($0.23) EPS. As a group, analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current year.

Insiders Place Their Bets

In related news, Director Casdin Capital, Llc bought 140,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $43.81 per share, for a total transaction of $6,133,400.00. Following the completion of the transaction, the director directly owned 3,507,164 shares in the company, valued at approximately $153,648,854.84. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 392 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the sale, the chief financial officer owned 34,942 shares in the company, valued at approximately $2,277,868.98. This represents a 1.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have purchased 2,056,420 shares of company stock worth $82,035,340 and have sold 72,382 shares worth $4,889,473. Company insiders own 29.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on WGS shares. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Guggenheim reduced their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Finally, Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.